Literature DB >> 26131597

Rehospitalizations Following Sepsis: Common and Costly.

Dong W Chang1, Chi-Hong Tseng, Martin F Shapiro.   

Abstract

OBJECTIVE: Although recent studies have shown that 30-day readmissions following sepsis are common, the overall fiscal impact of these rehospitalizations and their variability between hospitals relative to other high-risk conditions, such as congestive heart failure and acute myocardial infarction, are unknown. The objectives of this study were to characterize the frequency, cost, patient-level risk factors, and hospital-level variation in 30-day readmissions following sepsis compared with congestive heart failure and acute myocardial infarction.
DESIGN: A retrospective cohort analysis of hospitalizations from 2009 to 2011.
SETTING: All acute care, nonfederal hospitals in California. PATIENTS: Hospitalizations for sepsis (n = 240,198), congestive heart failure (n = 193,153), and acute myocardial infarction (n = 105,684) identified by administrative discharge codes.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcomes were the frequency and cost of all-cause 30-day readmissions following hospitalization for sepsis compared with congestive heart failure and acute myocardial infarction. Variability in predicted readmission rates between hospitals was calculated using mixed-effects logistic regression analysis. The all-cause 30-day readmission rates were 20.4%, 23.6%, and 17.7% for sepsis, congestive heart failure, and acute myocardial infarction, respectively. The estimated annual costs of 30-day readmissions in the state of California during the study period were $500 million/yr for sepsis, $229 million/yr for congestive heart failure, and $142 million/yr for acute myocardial infarction. The risk- and reliability-adjusted readmission rates across hospitals ranged from 11.0% to 39.8% (median, 19.9%; interquartile range, 16.1-26.0%) for sepsis, 11.3% to 38.4% (median, 22.9%; interquartile range, 19.2-26.6%) for congestive heart failure, and 3.6% to 40.8% (median, 17.0%; interquartile range, 12.2-20.0%) for acute myocardial infarction. Patient-level factors associated with higher odds of 30-day readmission following sepsis included younger age, male gender, Black or Native American race, a higher burden of medical comorbidities, urban residence, and lower income.
CONCLUSION: Sepsis is a leading contributor to excess healthcare costs due to hospital readmissions. Interventions at clinical and policy levels should prioritize identifying effective strategies to reduce sepsis readmissions.

Entities:  

Mesh:

Year:  2015        PMID: 26131597      PMCID: PMC5044864          DOI: 10.1097/CCM.0000000000001159

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  29 in total

Review 1.  Interventions to reduce 30-day rehospitalization: a systematic review.

Authors:  Luke O Hansen; Robert S Young; Keiki Hinami; Alicia Leung; Mark V Williams
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

2.  Long-term cognitive impairment and functional disability among survivors of severe sepsis.

Authors:  Theodore J Iwashyna; E Wesley Ely; Dylan M Smith; Kenneth M Langa
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

3.  Rehospitalizations among patients in the Medicare fee-for-service program.

Authors:  Stephen F Jencks; Mark V Williams; Eric A Coleman
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Socioeconomic status as an independent risk factor for hospital readmission for heart failure.

Authors:  E F Philbin; G W Dec; P L Jenkins; T G DiSalvo
Journal:  Am J Cardiol       Date:  2001-06-15       Impact factor: 2.778

6.  An administrative claims measure suitable for profiling hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction.

Authors:  Harlan M Krumholz; Zhenqiu Lin; Elizabeth E Drye; Mayur M Desai; Lein F Han; Michael T Rapp; Jennifer A Mattera; Sharon-Lise T Normand
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-03

7.  Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial.

Authors:  M Naylor; D Brooten; R Jones; R Lavizzo-Mourey; M Mezey; M Pauly
Journal:  Ann Intern Med       Date:  1994-06-15       Impact factor: 25.391

8.  A reengineered hospital discharge program to decrease rehospitalization: a randomized trial.

Authors:  Brian W Jack; Veerappa K Chetty; David Anthony; Jeffrey L Greenwald; Gail M Sanchez; Anna E Johnson; Shaula R Forsythe; Julie K O'Donnell; Michael K Paasche-Orlow; Christopher Manasseh; Stephen Martin; Larry Culpepper
Journal:  Ann Intern Med       Date:  2009-02-03       Impact factor: 25.391

9.  Identifying patients with severe sepsis using administrative claims: patient-level validation of the angus implementation of the international consensus conference definition of severe sepsis.

Authors:  Theodore J Iwashyna; Andrew Odden; Jeffrey Rohde; Catherine Bonham; Latoya Kuhn; Preeti Malani; Lena Chen; Scott Flanders
Journal:  Med Care       Date:  2014-06       Impact factor: 2.983

10.  Hospital readmission and healthcare utilization following sepsis in community settings.

Authors:  Vincent Liu; Xingye Lei; Hallie C Prescott; Patricia Kipnis; Theodore J Iwashyna; Gabriel J Escobar
Journal:  J Hosp Med       Date:  2014-04-04       Impact factor: 2.960

View more
  41 in total

1.  Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock.

Authors:  Brittany Mathias; Amber L Delmas; Tezcan Ozrazgat-Baslanti; Erin L Vanzant; Benjamin E Szpila; Alicia M Mohr; Frederick A Moore; Scott C Brakenridge; Babette A Brumback; Lyle L Moldawer; Philip A Efron
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

2.  Toward a Nuanced Understanding of the Role of Infection in Readmissions After Sepsis.

Authors:  Hallie C Prescott
Journal:  Crit Care Med       Date:  2016-03       Impact factor: 7.598

3.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

4.  Readmissions Among Sepsis Survivors: Risk Factors and Prevention.

Authors:  Andrew J Goodwin; Dee W Ford
Journal:  Clin Pulm Med       Date:  2018-05

5.  Readmission Diagnoses After Pediatric Severe Sepsis Hospitalization.

Authors:  Erin F Carlton; Joseph G Kohne; Manu Shankar-Hari; Hallie C Prescott
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

6.  An analysis of diagnoses that drive readmission: What can we learn from the hospitals in Southern New England with the highest and lowest readmission performance?

Authors:  Elizabeth M Goldberg; Blake Morphis; Rouba Youssef; Rebekah Gardner
Journal:  R I Med J (2013)       Date:  2017-08-01

7.  Variation in Postsepsis Readmission Patterns: A Cohort Study of Veterans Affairs Beneficiaries.

Authors:  Hallie C Prescott
Journal:  Ann Am Thorac Soc       Date:  2017-02

8.  The Association Between Neighborhood Socioeconomic Disadvantage and Readmissions for Patients Hospitalized With Sepsis.

Authors:  Panagis Galiatsatos; Amber Follin; Fahid Alghanim; Melissa Sherry; Carol Sylvester; Yamisi Daniel; Arjun Chanmugam; Jennifer Townsend; Suchi Saria; Amy J Kind; Edward Chen
Journal:  Crit Care Med       Date:  2020-06       Impact factor: 7.598

9.  From Barcelona to New York: 15 years of transition of sepsis performance improvement.

Authors:  R Phillip Dellinger; Shawana Hussain
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 10.  Update of Sepsis in the Intensive Care Unit.

Authors:  Kelly Roveran Genga; James A Russell
Journal:  J Innate Immun       Date:  2017-07-12       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.